A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in an Adult Population With BMI greater than or equal to 35
Latest Information Update: 10 Oct 2024
Price :
$35 *
At a glance
- Drugs Phentermine/topiramate (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms EQUIP
- Sponsors VIVUS
- 07 Oct 2024 According to VIVUS media release, the company today announced the availability of QSIVA (phentermine and topiramate modified-release) in Sweden, Denmark, Finland, Iceland, Norway, and Poland, making QSIVA accessible to patients with overweight and obesity who could benefit from weight loss, The approval in the Scandinavian countries and Poland was supported by compelling Phase III clinical data from more than 3700 patients who participated in the EQUIP and CONQUER trials
- 28 Apr 2017 Results (n=3040) assessing efficacy and safety of phentermine/topiramate extended release for weight loss in overweight and obese patients using pooled data from CONQUER, EQUIP and SEQUEL trials, published in the Diabetes Care
- 03 Nov 2011 Results published in the Obesity (Silver Spring, Md.).